Tag Archives: NIH

Driving Innovation through Federal Investments

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

Today, BIO submitted testimony to the Senate Committee on Appropriations on the importance of driving innovation through federal investments. Below are highlights of our written testimony. NIH:  A Driver of the Innovation Pipeline We must continue to invest in scientific discovery.  NIH-supported biomedical research builds the foundation of scientific and clinical knowledge that is widely communicated and used to improve the treatment of patients and underpin the development of new diagnostics, treatments, vaccines, and cures. Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

NIH & NSF SBIR/STTR Programs

InnovationZone_Logo_SBIR Companies_VERT_lockup

Leveraging Small Business to Bring Life-Saving Innovations to the Market. A key part of the National Institutes of Health (NIH) and the National Science Foundation (NSF)’s mission is the translation of basic discoveries into innovative technologies that improve human health, and the NIH and NSF Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs strive to do just that. NIH is the premier biomedical research funding organization in the world, and has a 2014 SBIR/STTR Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

Dent

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, co- chair of the Congressional Biomedical Research Caucus, joined BIO’s Fritz Bittenbender to discuss the biotech industry in Pennsylvania as well as recent legislative developments affecting the industry. Dent points to the recent omnibus spending agreement which allowed the Food and Drug Administration (FDA) to access user $85 million in user fees sequestered in 2013. These fees are paid to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Congress Passes Omnibus Spending Agreement

Jim Greenwood

This week, BIO President and CEO Jim Greenwood praised the Congress for passing the fundingbill for fiscal 2014, which would, among other things, allow the Food and Drug Administration (FDA) to access $85 million in user fees sequestered in 2013. In addition, BIO supports the agreement’s overall funding for: FDA, NIH, the biodefense enterprise; and improved program oversight of the important 340B program.  BIO also strongly supports the language in the bill providing the Department Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

SBIR Reauthorization Moves Forward

SBIR Reauthorization Moves Forward

NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states that small businesses that are majority-owned by multiple venture capital operating companies are eligible to apply for (1) these SBIR grants and (2) any other NIH SBIR funding opportunities announced after January 28, 2013.  The NIH grant solicitation announcement can be found here. With this re-issuance, small businesses that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,